EP4701734A2 - Verfahren zur behandlung von mit oxidiertem phosphatidylcholin assoziierten erkrankungen - Google Patents

Verfahren zur behandlung von mit oxidiertem phosphatidylcholin assoziierten erkrankungen

Info

Publication number
EP4701734A2
EP4701734A2 EP24733694.4A EP24733694A EP4701734A2 EP 4701734 A2 EP4701734 A2 EP 4701734A2 EP 24733694 A EP24733694 A EP 24733694A EP 4701734 A2 EP4701734 A2 EP 4701734A2
Authority
EP
European Patent Office
Prior art keywords
oxpc
antibody
antigen
binding fragment
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24733694.4A
Other languages
English (en)
French (fr)
Inventor
Pavlina KONSTANTINOVA
Sander Van Deventer
Andreia GOMES-DUARTE
Svitlana PASTEUNING-VUHMAN
Wouter POS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectory Therapeutics BV
Original Assignee
Vectory Therapeutics BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectory Therapeutics BV filed Critical Vectory Therapeutics BV
Publication of EP4701734A2 publication Critical patent/EP4701734A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24733694.4A 2023-04-28 2024-04-29 Verfahren zur behandlung von mit oxidiertem phosphatidylcholin assoziierten erkrankungen Pending EP4701734A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363498932P 2023-04-28 2023-04-28
PCT/IB2024/000205 WO2024224164A2 (en) 2023-04-28 2024-04-29 Methods of treating oxidized phosphatidylcholine-associated diseases

Publications (1)

Publication Number Publication Date
EP4701734A2 true EP4701734A2 (de) 2026-03-04

Family

ID=91581987

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24733694.4A Pending EP4701734A2 (de) 2023-04-28 2024-04-29 Verfahren zur behandlung von mit oxidiertem phosphatidylcholin assoziierten erkrankungen

Country Status (6)

Country Link
EP (1) EP4701734A2 (de)
KR (1) KR20260006615A (de)
CN (1) CN121240881A (de)
AU (1) AU2024260221A1 (de)
MX (1) MX2025012735A (de)
WO (1) WO2024224164A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4317185A3 (de) * 2017-10-18 2024-04-17 REGENXBIO Inc. Vollständig menschliche posttranslational modifizierte antikörpertherapeutika

Also Published As

Publication number Publication date
WO2024224164A3 (en) 2024-12-05
CN121240881A (zh) 2025-12-30
KR20260006615A (ko) 2026-01-13
WO2024224164A2 (en) 2024-10-31
MX2025012735A (es) 2026-02-03
AU2024260221A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
KR20210010434A (ko) 캡시드 탈아미드화가 감소된 신규 아데노-연관 바이러스(aav) 벡터 및 이의 용도
KR20240161976A (ko) Aav 캡시드 변이체 및 이의 용도
EP3403675B1 (de) Adeno-assoziiertes virusvirion zur verwendung bei der behandlung von epilepsie
US20250034559A1 (en) Compositions and methods for the treatment of tau-related disorders
CN111902539A (zh) 杂合调控元件
JP2021510539A (ja) デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
KR20230020394A (ko) Tau 결합 화합물
AU2023320453A1 (en) Compositions and methods for crossing the blood brain barrier
US20250084434A1 (en) Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
JP2019529385A (ja) Ｃｎｓ障害を治療するための方法及びベクター
WO2024229389A1 (en) Compositions and methods for the treatment of tau-related disorders
US20250235558A1 (en) Degron fusion constructs
KR20250069606A (ko) 타우 결합 화합물
US20240301042A1 (en) Selective targeting of oligomeric b-amyloid
TW202424201A (zh) Ａａｖ殼體變異體及其用途
JP2022543722A (ja) 機能的ニューロン死に関連する神経系疾患の予防および／または治療におけるＰｔｂｐ１阻害剤の使用
US20250281639A1 (en) Compositions and methods for treating chronic pain and for retrograde transduction of neurons
WO2021011365A1 (en) Treatment of diseases by expression of an enzyme which has a deoxyribonuclease (dnase) activity
AU2024260221A1 (en) Methods of treating oxidized phosphatidylcholine-associated diseases
CN112955169A (zh) 用于肌萎缩性侧索硬化疗法中的胆固醇24-水解酶的表达载体
US10799556B2 (en) Treatment of myotonic dystrophy
US20240309076A1 (en) Tau-specific antibody gene therapy compositions, methods and uses thereof
US20260043046A1 (en) Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
RU2773691C2 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ПОСРЕДСТВОМ ЭКСПРЕССИИ ФЕРМЕНТА, ОБЛАДАЮЩЕГО ДЕЗОКСИРИБОНУКЛЕАЗНОЙ (ДНКазной) АКТИВНОСТЬЮ, В ПЕЧЕНИ
WO2025229340A1 (en) Methods and compositions for treatment of a synucleinopathy and/or a disease associated with a gcase deficiency

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR